Evaluation of the CHF 5993 concentration in blood, after inhalation with two different devices, (NEXThaler® versus pMDI), with and without Aerochamber spacer device, in healthy volunteers.
CLI-05993BB1-01
Phase 1 other active
Quick answer
Evaluation of the CHF 5993 concentration in blood, after inhalation with two different devices, (NEXThaler® versus pMDI), with and without Aerochamber spacer device, in healthy volunteers. for Asthma is a Phase 1 program (other) at Chiesi Farmaceutici S.p.A with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Chiesi Farmaceutici S.p.A
- Indication
- Asthma
- Phase
- Phase 1
- Modality
- other
- Status
- active